| Autor: |
Karla, Aamuktha R., Pinard, Amélie, Boerio, Maura L., Hemelsoet, Dimitri, Tavernier, Simon J., De Pauw, Michel, Vereecke, Elke, Fraser, Stuart, Bamshad, Michael J., Guo, Dongchuan, Callewaert, Bert, Milewicz, Dianna M. |
| Zdroj: |
American Journal of Medical Genetics. Part A; Apr2024, Vol. 194 Issue 4, p1-7, 7p |
| Abstrakt: |
Aicardi–Goutières syndrome (AGS) is an autosomal recessive inflammatory syndrome that manifests as an early‐onset encephalopathy with both neurologic and extraneurologic clinical findings. AGS has been associated with pathogenic variants in nine genes: TREX1, RNASEH2B, RNASEH2C, RNASEH2A, SAMHD1, ADAR, IFIH1, LSM11, and RNU7‐1. Diagnosis is established by clinical findings (encephalopathy and acquired microcephaly, intellectual and physical impairments, dystonia, hepatosplenomegaly, sterile pyrexia, and/or chilblains), characteristic abnormalities on cranial CT (calcification of the basal ganglia and white matter) and MRI (leukodystrophic changes), or the identification of pathogenic/likely pathogenic variants in the known genes. One of the genes associated with AGS, SAMHD1, has also been associated with a spectrum of cerebrovascular diseases, including moyamoya disease (MMD). In this report, we describe a 31‐year‐old male referred to genetics for MMD since childhood who lacked the hallmark features of AGS patients but was found to have compound heterozygous SAMHD1 variants. He later developed mitral valve insufficiency due to recurrent chordal rupture and ultimately underwent a heart transplant at 37 years of age. Thus, these data suggest that SAMHD1 pathogenic variants can cause MMD without typical AGS symptoms and support that SAMHD1 should be assessed in MMD patients even in the absence of AGS features. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text